Greenwich LifeSciences CEO to Participate on Cancer Panel and to Present at Benzinga Biotech Conference
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced CEO Snehal Patel's participation in the Benzinga Biotech Small-Cap Conference on March 24, 2021. He will be involved in a 30-minute immunotherapy oncology panel at 10:25 am EST and a live 15-minute presentation at 12:35 pm EST, followed by a Q&A session. The company is focused on developing GP2, an immunotherapy intended to prevent breast cancer recurrences in previously treated patients. The Phase IIb trial showed promising results with no recurrences after five years.
- None.
- None.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that CEO Snehal Patel will participate in multiple events at the Benzinga Biotech Small-Cap Conference.
Mr. Patel’s interview that was previously recorded on March 11, 2021 on Benzinga’s Power Hour is now available here: https://www.youtube.com/watch?v=P--GSgcTWoQ&t=12s
Benzinga has also published an article on the Company which can be viewed here:
https://www.benzinga.com/general/biotech/21/03/20282424/greenwich-lifesciences-could-see-another-spike-in-stock-in-early-april
On March 24, 2021, Mr. Patel will participate in the Benzinga Biotech Small-Cap Conference in a 30 minute immunotherapy oncology panel at 10:25 am EST. Mr. Patel will also participate in a live 15 minute virtual presentation at 12:35 pm EST to Benzinga’s small-cap investors followed by Q&A. For more information, please visit the conference website at:
https://www.benzinga.com/events/small-cap/biotech/#agenda
About Breast Cancer and HER2/neu Positivity
One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. HER2/neu (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
For more information on Greenwich LifeSciences, please visit the Company’s website at www.greenwichlifesciences.com and follow us on Twitter at https://twitter.com/GreenwichLS.
Forward-Looking Statement Disclaimer
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005428/en/
FAQ
What is Greenwich LifeSciences' stock symbol?
When is CEO Snehal Patel speaking at the Benzinga Biotech Small-Cap Conference?
What is the focus of Greenwich LifeSciences' GP2 immunotherapy?
What were the results of the Phase IIb trial for GP2?
What type of panel will Snehal Patel participate in at the conference?
